CDKN2A and thyroid gland carcinoma: This increased thyroid cancer risk remained higher until 60 months after the index CMM, which could suggest the involvement of cancer-promoting genetic abnormalities (i.e., BRAFv600e, CDKN2A) which could potentially be involved in the pathogenesis of both malignancies (23–26).